We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
Metrion Biosciences is a pharmaceutical research organisation that provide a high quality drug discovery services for ion channel targets to clients on a fee-for-service or collaboration basis.
days to go: Expired investment: £465,150
Landbay is a Buy-to Mortgage (BTM) lending platform that provides investors access to a flow of whole-loan high-quality BTL mortgages that can be securitised or held on a balance sheet. Landbay asserts that it does not deploy any of its own balance sheet nor take any credit risk. The company has completed over £600 million of mortgages to date. It argues that it has the mortgage funding, technology and capacity to grow significantly in the £250 billion mortgage market. The company was rated 'Excellent' on consumer review website Trustpilot. It will use 50% of the investment towards technology upgrade, 25% towards marketing and brand development, and 25% towards general marketing expenses.
days to go: Expired investment: £5,129,548
Nude is a savings account and financial application designed for ~13 million 18-35-year-olds who want to own a home in the UK. The company is rebuilding the home-buying experience and assist its clients from planning to the move-in stage of home buying. The company has applied for a banking licence to launch Nude mortgages and plans to support people through all of life's big moments, like weddings, children's accounts and retirement plans as well. In 2019, Nude raised £1.7 million and was awarded an innovation grant of ~£440,000 from Scottish Enterprise. The company is registered with the Financial Conduct Authority(FCA) and has 7,500+ subscribers on its newsletter. It will use 50% of the investment to build its savings platform, 20% for operational costs, 20% in marketing initiatives, and 10% in building its data & behavioural science platform. 
days to go: Expired investment: £3,539,200
Providing dental professionals with an online Personal Development Plan for their Continuing Professional Development. Dentinal Tubules currently has more than 2,100 individuals registered to use the service and over 2,700 dental practice professionals that are paying for a subscription. Dentinal Tubules hosts more than 1,500 educational and certified videos to help with a professional's CPD, in addition they also offer live courses, a livestream and an annual congress. Investments will be used to enhance, develop and bring the technology in-house.
days to go: Expired investment: £155,820
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go: Expired investment: £543,670
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
CrowdProperty is a specialist property project lending platform that matches quality property professionals undertaking quality property projects with institutional/private investors of capital for value-creating property projects. It seeks to ensure profits for borrowers, lenders, the under-supplied UK housing environment, and the UK economy through its business model. The company claims to have recently closed a £300 million funding line from a global asset manager. It has lent upwards of £140 million with £180 million+ originated facilities, gained recognition by Deloitte Fast50 and FT1000 as a 'High Growth Business', and built a proprietary and scalable technology platform. CrowdProperty has also launched CrowdProperty Australia, leveraging its asset-class expertise, scalable proprietary technology and IP from the UK business in the Australian market. The company states it will use the investment to grow its property team, evolve its technology platform further, acquire more customers, and grow its business.
days to go: Expired investment: £1,815,319
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph